These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62 related articles for article (PubMed ID: 1311478)
1. Strong donor mononuclear cell reactivity for herpes simplex virus antigen in immune donor/recipient pairs is associated with acute graft-versus-host disease. Boström L; Ringdén O; Forsgren M Transplant Proc; 1992 Feb; 24(1):376-7. PubMed ID: 1311478 [No Abstract] [Full Text] [Related]
2. Strong donor mononuclear cell reactivity for herpes simplex virus (HSV) antigen in HSV immune donors combined with recipient seropositivity for HSV is associated with acute graft-versus-host disease. Boström L; Ringdén O; Forsgren M Scand J Immunol; 1991 Jul; 34(1):45-52. PubMed ID: 1648786 [TBL] [Abstract][Full Text] [Related]
3. Graft-versus-host-disease prophylaxis for matched unrelated donor bone marrow transplantation: comparison between cyclosporine-methotrexate and cyclosporine-methotrexate-methylprednisolone. Leelasiri A; Greer JP; Stein RS; Goodman S; Brandt SA; Edwards JR; Wolff SN Bone Marrow Transplant; 1995 Mar; 15(3):401-5. PubMed ID: 7599565 [TBL] [Abstract][Full Text] [Related]
4. A new marrow T cell depletion method using anti-CD6 monoclonal antibody-conjugated magnetic beads and its clinical application for prevention of acute graft-vs.-host disease in allogeneic bone marrow transplantation: results of a phase I-II trial. Sao H; Kitaori K; Kasai M; Shimokawa T; Kato C; Yamanishi H; Ueda R; Morishima Y Int J Hematol; 1999 Jan; 69(1):27-35. PubMed ID: 10641440 [TBL] [Abstract][Full Text] [Related]
7. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation. Schwinghammer TL; Bloom EJ Clin Pharm; 1993 Oct; 12(10):736-61. PubMed ID: 8258255 [TBL] [Abstract][Full Text] [Related]
8. Evidence that donor intrinsic response to G-CSF is the best predictor of acute graft-vs-host disease following allogeneic peripheral blood stem cell transplantation. Dhédin N; Chamakhi I; Perreault C; Roy DC; Sauvageau G; Ducruet T; Busque L; Fish D; Bélanger R; Roy J Exp Hematol; 2006 Jan; 34(1):107-14. PubMed ID: 16413397 [TBL] [Abstract][Full Text] [Related]
9. Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease. van Burik JA; Carter SL; Freifeld AG; High KP; Godder KT; Papanicolaou GA; Mendizabal AM; Wagner JE; Yanovich S; Kernan NA Biol Blood Marrow Transplant; 2007 Dec; 13(12):1487-98. PubMed ID: 18022579 [TBL] [Abstract][Full Text] [Related]
10. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease. Aschan J; Ringdén O Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365 [TBL] [Abstract][Full Text] [Related]
11. Marrow donor immunity to herpes simplex virus: association with acute graft-versus-host disease. Gratama JW; Sinnige LG; Weijers TF; Zwaan FE; van Heugten JG; Stijnen T; D'Amaro J; The TH; Hekker AC; de Gast GC Exp Hematol; 1987 Aug; 15(7):735-40. PubMed ID: 3038583 [TBL] [Abstract][Full Text] [Related]
12. Low-dose donor CD8+ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase. Gallardo D; García-López J; Sureda A; Canals C; Ferra C; Cancelas JA; Berlanga JJ; Brunet S; Boqué C; Picón M; Torrico C; Amill B; Martino R; Martínez C; Martín-Henao G; Domingo-Albós A; Grañena A Bone Marrow Transplant; 1997 Dec; 20(11):945-52. PubMed ID: 9422473 [TBL] [Abstract][Full Text] [Related]
13. Effect of selective T cell depletion of host and/or donor bone marrow on lymphopoietic repopulation, tolerance, and graft-vs-host disease in mixed allogeneic chimeras (B10 + B10.D2----B10). Ildstad ST; Wren SM; Bluestone JA; Barbieri SA; Stephany D; Sachs DH J Immunol; 1986 Jan; 136(1):28-33. PubMed ID: 2933464 [TBL] [Abstract][Full Text] [Related]
14. Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation. Weisdorf D; Filipovich A; McGlave P; Ramsay N; Kersey J; Miller W; Blazar B Bone Marrow Transplant; 1993 Nov; 12(5):531-6. PubMed ID: 8298565 [TBL] [Abstract][Full Text] [Related]
15. Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only condition regimen. Low incidence of failed engraftment and severe acute GVHD. Topolsky D; Crilley P; Styler MJ; Bulova S; Brodsky I; Marks DI Bone Marrow Transplant; 1996 Apr; 17(4):549-54. PubMed ID: 8722353 [TBL] [Abstract][Full Text] [Related]
16. Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation. Atkinson K; Downs K Bone Marrow Transplant; 1995 Dec; 16(6):755-8. PubMed ID: 8750265 [TBL] [Abstract][Full Text] [Related]
17. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors. Koehler M; Hurwitz CA; Krance RA; Coustan-Smith E; Williams LL; Santana V; Ribeiro RC; Brenner MK; Heslop HE Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937 [TBL] [Abstract][Full Text] [Related]
18. A role of herpes virus serology for the development of acute graft-versus-host disease. Leukaemia Working Party of the European Group for Bone Marrow Transplantation. Boström L; Ringdén O; Gratama JW; Jacobsen N; Prentice HG; Zwaan FE; Nilsson B Bone Marrow Transplant; 1990 May; 5(5):321-6. PubMed ID: 2190659 [TBL] [Abstract][Full Text] [Related]
19. In vivo/ex vivo T cell depletion for GVHD prophylaxis influences onset and course of active cytomegalovirus infection and disease after BMT. Hertenstein B; Hampl W; Bunjes D; Wiesneth M; Duncker C; Koszinowski U; Heimpel H; Arnold R; Mertens T Bone Marrow Transplant; 1995 Mar; 15(3):387-93. PubMed ID: 7599563 [TBL] [Abstract][Full Text] [Related]
20. The impact of T-cell depletion on the effects of HLA DR beta 1 and DQ beta allele matching in HLA serologically identical unrelated donor bone marrow transplantation. Gajewski J; Gjertson D; Cecka M; Tonai R; Przepiorka D; Hunt L; Giralt S; Chan KW; Feig S; Territo M; Andersson B; van Besien K; Khouri I; Fischer H; Babbitt L; Ippolitti C; Schiller G; Lill M; Warkentin D; Neumann J; Petz L; Terasaki P; Champlin R Biol Blood Marrow Transplant; 1997 Jun; 3(2):76-82. PubMed ID: 9267667 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]